2025
SJR Q2
JCR Q2 · 3,4
515 eşleşen makale
SCIE
Dergi ayrıntısı
Journal of Pharmaceutical and Biomedical Analysis
- Yayıncı
- Elsevier B.V.
- Ülke
- Netherlands · Western Europe
- Tür
- journal
- ISSN
-
073170851873264X
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,604
- Quartile Q2
- H-Index 160
- Atıf/yayın 3,66
- Doküman (3y) 1.706
- Atıf (3y) 6.442
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,4
- 5Y JIF 3,3
- JCI 0,82
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
Alanlar
WoS kategorileri
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,604 | 3,4 | 3,3 | 0,82 | Q2 | 160 |
| 2024 | Q2 | Q2 | 0,628 | 3,1 | 3,1 | 0,86 | Q2 | 154 |
| 2023 | Q2 | Q2 | 0,584 | 3,1 | 3,1 | 0,88 | Q1 | 154 |
| 2022 | Q2 | Q2 | 0,608 | 3,4 | 3,3 | 0,91 | Q1 | 154 |
| 2021 | Q2 | Q2 | 0,657 | 3,6 | 3,6 | 0,94 | Q1 | 154 |
| 2020 | Q1 | Q2 | 0,777 | 3,9 | 3,6 | 0,98 | Q1 | 154 |
| 2019 | Q1 | Q2 | 0,795 | 3,2 | 3,1 | 1 | Q1 | 154 |
| 2018 | — | Q2 | — | 3 | 3,1 | 1,01 | Q1 | — |
| 2017 | Q1 | Q2 | 0,919 | 2,8 | 2,9 | 1,06 | Q1 | 154 |
| 2016 | Q1 | Q1 | 0,92 | 3,3 | 3 | — | — | 154 |
| 2015 | Q1 | Q1 | 1,052 | 3,2 | 2,9 | — | — | 154 |
| 2014 | Q1 | Q1 | 1,056 | 3 | 2,9 | — | — | 154 |
| 2013 | Q1 | Q2 | 1,235 | 2,8 | 2,9 | — | — | 154 |
| 2012 | Q1 | Q2 | 1,198 | 2,9 | 2,9 | — | — | 154 |
| 2011 | Q1 | Q2 | 1,191 | 3 | 3 | — | — | 154 |
| 2010 | Q1 | Q2 | 1,118 | 2,7 | 2,7 | — | — | 154 |
| 2009 | — | Q2 | — | 2,5 | 2,5 | — | — | — |
| 2008 | — | Q2 | — | 2,6 | 2,5 | — | — | — |
| 2007 | — | Q2 | — | 2,8 | 2,5 | — | — | — |
| 2006 | — | Q2 | — | 2 | — | — | — | — |
| 2005 | — | Q2 | — | 1,9 | — | — | — | — |
| 2004 | — | Q2 | — | 1,5 | — | — | — | — |
| 2003 | — | Q2 | — | 1,4 | — | — | — | — |
| 2002 | — | Q2 | — | 1,4 | — | — | — | — |
| 2001 | — | Q3 | — | 1,2 | — | — | — | — |
| 2000 | — | Q3 | — | 1 | — | — | — | — |
| 1999 | — | Q3 | — | 1 | — | — | — | — |
| 1998 | — | Q3 | — | 0,9 | — | — | — | — |
| 1997 | — | Q3 | — | 1 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q2 | 48/110 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 143/356 |
| 2024 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q2 | 45/111 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 134/352 |
| 2023 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 37/106 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 126/354 |
| 2022 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 29/86 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 125/278 |
| 2021 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 32/87 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 143/279 |
| 2020 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 24/87 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 113/276 |
| 2019 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 26/86 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 100/271 |
| 2018 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 24/84 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 105/267 |
| 2017 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | Q1 | 23/81 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 105/261 |
| 2016 | CHEMISTRY, ANALYTICAL | SCIE | Q1 | — | 18/76 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 70/257 |
| 2015 | CHEMISTRY, ANALYTICAL | SCIE | Q1 | — | 14/75 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 70/255 |
| 2014 | CHEMISTRY, ANALYTICAL | SCIE | Q1 | — | 16/74 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 81/255 |
| 2013 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 22/76 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 91/256 |
| 2012 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 19/75 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 78/261 |
| 2011 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 20/73 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/261 |
| 2010 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 20/73 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 91/252 |
| 2009 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 23/70 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 111/237 |
| 2008 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 18/70 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/219 |
| 2007 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 19/70 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 67/205 |
| 2006 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 24/68 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 97/199 |
| 2005 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 21/70 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 97/193 |
| 2004 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 28/70 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 108/187 |
| 2003 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 30/67 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 107/185 |
| 2002 | CHEMISTRY, ANALYTICAL | SCIE | Q2 | — | 30/68 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 105/188 |
| 2001 | CHEMISTRY, ANALYTICAL | SCIE | Q3 | — | 35/68 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 110/186 |
| 2000 | CHEMISTRY, ANALYTICAL | SCIE | Q3 | — | 41/65 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 116/181 |
| 1999 | CHEMISTRY, ANALYTICAL | SCIE | Q3 | — | 38/66 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 102/175 |
| 1998 | CHEMISTRY, ANALYTICAL | SCIE | Q3 | — | 37/65 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 102/178 |
| 1997 | CHEMISTRY, ANALYTICAL | SCIE | Q3 | — | 35/61 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 91/157 |